PT1086092E - Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao - Google Patents

Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao

Info

Publication number
PT1086092E
PT1086092E PT99927784T PT99927784T PT1086092E PT 1086092 E PT1086092 E PT 1086092E PT 99927784 T PT99927784 T PT 99927784T PT 99927784 T PT99927784 T PT 99927784T PT 1086092 E PT1086092 E PT 1086092E
Authority
PT
Portugal
Prior art keywords
tiepine
benzo
dioxide
utilization
compounds
Prior art date
Application number
PT99927784T
Other languages
English (en)
Inventor
Heuer Dr Hubert
Wendelin Frick
Alfons Enhsen
Heiner Glombik
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PT1086092E publication Critical patent/PT1086092E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D337/00Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02Seven-membered rings
    • C07D337/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT99927784T 1998-06-10 1999-05-28 Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao PT1086092E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
PT1086092E true PT1086092E (pt) 2003-03-31

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99927784T PT1086092E (pt) 1998-06-10 1999-05-28 Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao
PT99927802T PT1086113E (pt) 1998-06-10 1999-05-29 Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT99927802T PT1086113E (pt) 1998-06-10 1999-05-29 Derivados de benzotiepina-1,1-dioxido processos para a sua preparacao medicamentos contendo estes compostos e sua utilizacao

Country Status (26)

Country Link
US (1) US6387944B1 (pt)
EP (2) EP1086092B1 (pt)
JP (2) JP4374426B2 (pt)
KR (2) KR100681721B1 (pt)
CN (2) CN1127497C (pt)
AR (2) AR018633A1 (pt)
AT (2) ATE227715T1 (pt)
AU (2) AU753275B2 (pt)
BR (2) BR9912188B1 (pt)
CA (2) CA2334775C (pt)
CZ (2) CZ297989B6 (pt)
DE (3) DE19825804C2 (pt)
DK (2) DK1086092T3 (pt)
ES (2) ES2182535T3 (pt)
HK (2) HK1039490A1 (pt)
HU (2) HU229761B1 (pt)
ID (2) ID28695A (pt)
IL (1) IL140078A (pt)
NO (1) NO327075B1 (pt)
NZ (1) NZ508681A (pt)
PL (2) PL196074B1 (pt)
PT (2) PT1086092E (pt)
RU (2) RU2215001C2 (pt)
TR (2) TR200003634T2 (pt)
WO (2) WO1999064410A1 (pt)
ZA (2) ZA200007060B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
BR0116325A (pt) * 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
JP2005501861A (ja) * 2001-08-22 2005-01-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 1,4−ベンゾチエピン1,1−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
NZ531796A (en) 2001-09-08 2005-10-28 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
HUE030062T2 (en) 2010-11-08 2017-04-28 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP6954927B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
BR112020024479A2 (pt) 2018-06-20 2021-03-02 Albireo Ab hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
EP3921027B1 (en) 2019-02-06 2023-07-19 Albireo AB Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
ES2937153T3 (es) 2019-02-06 2023-03-24 Albireo Ab Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
HUE065571T2 (hu) 2019-12-04 2024-06-28 Albireo Ab Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996008484A1 (en) * 1994-09-13 1996-03-21 Monsanto Company Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
NZ331813A (en) * 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6096780A (en) * 1998-08-20 2000-08-01 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use

Also Published As

Publication number Publication date
EP1086092A1 (de) 2001-03-28
JP3374129B2 (ja) 2003-02-04
EP1086113B1 (de) 2004-02-11
HK1039490A1 (en) 2002-04-26
WO1999064410A1 (de) 1999-12-16
JP4374426B2 (ja) 2009-12-02
CZ20004591A3 (cs) 2001-04-11
CN1305469A (zh) 2001-07-25
HUP0102554A3 (en) 2002-12-28
CA2334773C (en) 2009-05-26
WO1999064409A3 (de) 2000-03-02
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
CA2334775C (en) 2009-10-13
AU752633B2 (en) 2002-09-26
NO20006251L (no) 2001-02-07
CZ20004592A3 (cs) 2001-04-11
US6387944B1 (en) 2002-05-14
AU4503199A (en) 1999-12-30
ATE227715T1 (de) 2002-11-15
AR018634A1 (es) 2001-11-28
ID28695A (id) 2001-06-28
ES2182535T3 (es) 2003-03-01
PT1086113E (pt) 2004-06-30
AR018633A1 (es) 2001-11-28
CZ297925B6 (cs) 2007-05-02
KR100681721B1 (ko) 2007-02-15
HUP0102256A1 (hu) 2001-12-28
KR20010052701A (ko) 2001-06-25
CN1127497C (zh) 2003-11-12
WO1999064409A2 (de) 1999-12-16
HK1036799A1 (en) 2002-01-18
NZ508681A (en) 2002-06-28
BR9911123B1 (pt) 2010-12-14
AU4501999A (en) 1999-12-30
HUP0102554A1 (hu) 2001-10-28
PL196057B1 (pl) 2007-11-30
BR9912188A (pt) 2001-04-10
DK1086113T3 (da) 2004-05-24
EP1086113A2 (de) 2001-03-28
NO327075B1 (no) 2009-04-20
BR9912188B1 (pt) 2010-12-14
JP2002517491A (ja) 2002-06-18
AU753275B2 (en) 2002-10-10
HU228570B1 (en) 2013-04-29
DE59908522D1 (de) 2004-03-18
ID26876A (id) 2001-02-15
DE59903411D1 (de) 2002-12-19
TR200003632T2 (tr) 2001-04-20
CN1305487A (zh) 2001-07-25
EP1086092B1 (de) 2002-11-13
DE19825804A1 (de) 1999-12-16
ZA200007060B (en) 2001-07-18
DE19825804C2 (de) 2000-08-24
CA2334773A1 (en) 1999-12-16
DK1086092T3 (da) 2003-03-10
IL140078A0 (en) 2002-02-10
JP2002517490A (ja) 2002-06-18
PL196074B1 (pl) 2007-12-31
TR200003634T2 (tr) 2001-06-21
ES2215387T3 (es) 2004-10-01
HUP0102256A3 (en) 2002-04-29
RU2220141C2 (ru) 2003-12-27
ZA200007061B (en) 2001-07-18
CZ297989B6 (cs) 2007-05-16
PL344827A1 (en) 2001-11-19
CN1152039C (zh) 2004-06-02
HU229761B1 (hu) 2014-06-30
RU2215001C2 (ru) 2003-10-27
ATE259372T1 (de) 2004-02-15
KR20010052682A (ko) 2001-06-25
NO20006251D0 (no) 2000-12-08
CA2334775A1 (en) 1999-12-16
BR9911123A (pt) 2006-01-03
IL140078A (en) 2004-08-31

Similar Documents

Publication Publication Date Title
PT1086092E (pt) Derivados de 1,1-dioxido-benzo (b) tiepina processo para a sua producao medicamentos contendo esses compostos e a sua utilizacao
BR9707839A (pt) Primido-Ú5,4-D¾-primidas medicamentos contendo esses compostos sua aplicação e processo para a sua preparação
BR9505051A (pt) Composto derivado de 2,4-oxazolidinodiona processo para a sua produção e composição farmacêutica
BR9807845B1 (pt) pó de tántalo e processo para a sua produção.
BR9605906A (pt) Compostos benzo-heterociclicos substituídos por aminoalquila utilizaçao processo para sua fabricaçao e agentes com açao antimicótica e redutora do colesterol contendo os mesmos
BR9804378B1 (pt) compostos, processo para sua produção e uso.
BR9400616A (pt) Processo para a preparação de 1,1,1,4,4,4-hexafluorbuteno-2
PT983059E (pt) Processo para a producao de pastilhas de flurbiprofeno
BR9205458A (pt) Novos compostos A83543 e processo para a produção dos mesmos.
ITMI950056A0 (it) Processo per la produzione di 10-oxo-10,11-diidro-sh- -dibenz(b,f) azepin-5-carbossiammide
PT770687E (pt) Processo para a producao de nicotinamida
BR9104948A (pt) Compostos,processo para a sua producao,agente farmaceutico e processo para a sua producao
BR9303456A (pt) Compostos,processo para sua preparacao,medicamentos,processo para sua preparacao e emprego
PT1015433E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocin-10-ois substituidos processo para a sua producao e sua utilizacao como medicamentos
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
PT1027315E (pt) Processo para a producao de n-butanol.
BR9612235A (pt) Processo para a obtenção de ácido 2-hidróxi-4-metiltiobutírico (mha)
BR9305161A (pt) Composto, composição farmacêutica e processo para a preparação do composto
BR9004539A (pt) Processo para a obtencao de 1,1,1,2-tetrafluoretano
BR9804873A (pt) Processo para a produ-Æo de ironas
BR9814774B1 (pt) processo para a preparação de (-)cis-3-hidróxi-1-metil-4-(2,4,6-trimetoxifenil)-piperidi na e intermediários para sua preparação.
BR9600732A (pt) Processo para proporcionar a estabilidade de pó de polímero aperfeiçoada
BR9003360A (pt) Processo para a obtencao de 1,1,1-trifluor-2-cloroetano
BR9608468A (pt) Processo para a preparação de n-metil-2-(3,4-dimetoxifenil)-etilamina
BR9800565B1 (pt) processo para a produÇço de compostos de halogeno-o-hidroxidifenila.